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The gene for a single-chain antibody (VHK) to a conformational epitope on the type A12 foot-and-mouth disease virus
(FMDV) particle was assembled and expressed in Escherichia coli. The VHK, purified from periplasmic extracts immunoprecip-
itated virus as efficiently as its parental monoclonal antibody (MAb) and exhibited the same binding specificity when tested
against a panel of natural and genetically engineered virus particles. The VHK neutralized type A12 virus in the presence of
goat anti-mouse IgG; however, in the absence of the second antibody, only weak neutralizing activity was detected. Prelimi-
nary analysis of the mechanism of viral neutralization indicated that both the MAb and the VHK neutralize by the same
mechanism. Small amounts of the VHK allowed infection of cells via Fc receptor-mediated adsorption in the presence of
the second antibody. These data represent the first report of a single-chain neutralizing antibody for a picornavirus and
provide insights into the mechanisms of viral neutralization and virus uptake. q 1996 Academic Press, Inc.
Foot-and-mouth disease virus (FMDV) is a picornavi- interactions between the G–H loops of VP1 and VP3
have been postulated based on rearrangements of bothrus that causes a debilitating and economically important
loops upon reduction of an S–S bond binding the G –Hdisease of livestock. The viral structure at atomic resolu-
loop of VP1 to VP2 in type O1 FMDV, and on the observa-tion has been determined by X-ray crystallography (1,
tion that the structure of a portion of the VP1 G–H loop19), and experiments with monoclonal antibodies (MAbs)
and the VP3 G–H loop from type A22 , which has nothat are capable of neutralizing virus infection in vitro
disulfide bond between VP1 and VP2, is identical to thathave been used to map multiple neutralizing epitopes
seen in reduced type O1 (11). Our data suggest, however,on the virion surface (23). One of the dominant epitopes
that the G–H loop of VP1 is not involved in the 2PD11recognized by these MAbs is found between the bG and
epitope, since antigenic chimeras of type A12 containingbH strands of VP1 in a flexible surface-exposed loop (G –
the substituted VP1 G–H loops from types O or C retainH loop) that has been demonstrated to be antigenic and
2PD11 reactivity (25). In addition, 2PD11 appears to neu-immunogenic in many systems (7). This epitope, how-
tralize virus by a mechanism which involves neither ag-ever, is not uniformly recognized by sera from vaccinated
gregation nor blocking of virus adsorption to cells (4) andor infected swine (24), and by itself, is not completely
is able to enhance the infection of virus on cells thatprotective in vaccine preparations (25).
express the immunoglobulin Fc receptor (FcR; 3, 21).Our laboratory has characterized a panel of neutraliz-
To evaluate the structure and function of 2PD11, weing MAbs to the serotype A12 virus (4, 5). One of these
have amplified the cDNA molecules corresponding to theMAbs, produced by hybridoma 2PD11, recognizes a con-
variable regions of the heavy and light (k) chains of theformational epitope displayed only by intact viral capsids.
immunoglobulin molecule and expressed them as bio-This epitope has been mapped, using a panel of neutral-
logically active single-chain molecules in bacteria.ization escape mutants, to two amino acid residues posi-
To this end, 2PD11 present in hybridoma culture fluidtioned in the G–H loop of VP3 (5). The binding site for
was purified by affinity chromatography on protein A –2PD11 is topologically close to the G–H loop of VP1 and
Sepharose, and the heavy (H) and light (L) chains were
resolved by polyacrylamide gel electrophoresis (PAGE)
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sense oligonucleotide (VL6; Table 1). This oligonucleo-848, Greenport, NY 11944-0848. Fax: (516) 323-2507. E-mail: bbaxt@
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TABLE 1
Oligonucleotides Used for PCR Amplification of 2PD11 mRNAa
Oligo Sense Chainb Sequencec
SstI
VL6 / L (VL 5*) CC AGA TGT GAG CTC GTC ATG ACC CAG TCT CCA
E L V M T Q S P
XbaI
k 3* 0 L (CL 3*) AAG TTG TCC TTA CTC ACA ATT AAG ATC TG CCG CG
F N R N E C *
SstI
P98 / L (VL 5*) GCC GAG CTC GTC ATG ACC CAG TCT CCA AAA TCC ATG TCC ATG TC
E L V M T Q S P K S M S M
SpeI
IgG2b 3* 0 H (CH1 3*) TGT TAG TTG GGG ACA GGA TGA TCA TTC CTC
T M K P C P T S
XhoI
VH3 / H (VH 5*) CAG GTC CAA CTC GAG CAG CCT GGG GCT
L E Q P G A
XhoI
P128 / H (VH 5*) CGG CTC GAG CAG CCT GGG GCT GAG CTG
L E Q P G A E L
SpeI
P129 0 H (CH1 3*) TAA AGT TGT TAG TTG GGG ACA GGA TGA TCA GGC
I S T M K P C P T S
MVH- SstI
link 0 H (VH-CH) TTT TGC TGT GGG GGT AGA CAG ATA GGT GAC CGG CTC GAG GTC TAC TGG GTC
K T T P P S V Y P L A E L
a Restriction endonuclease sites used for cloning are underlined, and the specific enzyme is shown above the sequence.
b The location of the primer binding on either the heavy (H) or light (L) chains.
c Antisense sequences are shown in italics and the translated sequence is shown below the nucleotide sequence.
k 3* (Table 1), was used to amplify cDNA fragments cDNA produced with an IgG2b-specific antisense primer
(IgG2b 3*; Table 1) was amplified with a panel of eightfrom a single-stranded cDNA preparation, prepared from
hybridoma cellular RNA (9) using Moloney murine leuke- different N-terminal oligonucleotides (18). Two of these
produced strong amplification products of the expectedmia virus reverse transcriptase (Life Technologies, Inc.,
Gaithersburg, MD), by PCR (1 min at 947, 1 min at 557, 1 size, and the PCR product from one of them (VH3, Table
1) was digested with SpeI and XhoI, ligated to pCombmin at 727 for 30 cycles using Taq polymerase). This
amplification yielded a product of the predicted size DNA digested with the same enzymes, and used to trans-
form DH5a cells. Three plasmids, selected from thesewhich was cloned into the pCRII DNA vector (Invitrogen,
San Diego, CA). Two recombinant plasmids were identi- transformations, contained H chain cDNAs, but se-
quence analyses revealed that none of these productsfied and partially sequenced using Sequenase (Amer-
sham, Arlington Heights, IL). These analyses revealed contained an ORF. Therefore, an additional set of longer
primers (P128 and P129; Table 1) was designed and usedsequences that encoded the expected N-terminus, but
both cloned cDNA products contained frameshifts that to amplify cDNA molecules that were cloned into pComb
DNA. Multiple plasmids harboring the P128/P129 PCRproduced stop codons within the predicted open reading
frames (ORF). Therefore, a longer 5* oligonucleotide (P98; product were identified, and one, number 21, was se-
quenced through the entire amplified region to reveal aTable 1) was synthesized and used with k 3* to PCR-
amplify cDNA fragments that were digested with SstI and 648-nucleotide ORF corresponding to an entire VH/CH1
cDNA.XbaI and ligated to pComb DNA digested with the same
restriction endonucleases (2, 17). Sequence analyses of The VH region of plasmid 21 DNA was amplified using
the oligonucleotides P128 and MHV-link (Table 1), pro-one of the recombinant plasmids (50), recovered from
competent Escherichia coli DH5a bacterial cells trans- ducing a PCR product encoding the framework 1–4 re-
gions of the H chain followed by an SstI site to facilitateformed with these ligation mixes, revealed that it con-
tained an ORF of 648 nucleotides, extending from VL in-frame linkage to the L chain. The amplified fragment
was inserted into plasmid 50, containing the L chainframework 1 to the constant region of the k chain.
Amino acid sequence data were unavailable for the cDNA (see above), and recombinant plasmids containing
the VH-k fusion were identified. One of these plasmids,2PD11 H chain, since the N-terminus was blocked, so
AID VY 8183 / 6a20$$$222 09-16-96 22:49:43 vira AP: Virology
550 SHORT COMMUNICATION
FIG. 1. Sequence of the protein encoded by VHK 6. The asterisks indicate the positions of C residues believed to be used in intrachain disulfide
bonding.
designated VHK 6, which was sequenced through the secondary antibody, the single-chain antibody is as ac-
tive, on a weight basis, as 2PD11 (Fig. 3). To evaluateentire reamplified segment corresponding to regions 1–
4 of the H chain and the first b strand of the CH1 domain, the specificity of the VHK, we tested its ability to immuno-
precipitate different serotypes and antigenic chimeras ofwas selected for all further analyses.
The VHK 6 plasmid contains a 1098-nucleotide ORF FMDV. The results in Fig. 4 show that both the VHK and
2PD11 were able to immunoprecipitate type A12 and twopositioned behind the E. coli lac promoter/pelB leader
sequence of pComb (Fig. 1). The promoter/leader cas- antigenic chimeras containing the VP1 G–H loops from
either O1 (A/O) or C3 (A/C) (25). In contrast neither anti-sette permits the secretion of a VHK molecule of a pre-
dicted molecular mass of 38,225 Da into the periplasmic body was able to react with either types O1 or C3 , consis-
tent with the previously established specificity (4) andcompartment of E. coli D29A1 cells transformed with the
pComb derivatives and induced with isopropylthiogalac- epitope mapping (5) of MAb 2PD11. In addition, the VHK
was unable to immunoprecipitate a 2PD11-resistant MAbtoside (IPTG) (13). To examine the properties of the VHK
6 product, periplasmic fractions were isolated from IPTG- escape mutant (not shown).
The ability of the purified VHK to neutralize type A12induced cultures transformed with either VHK 6 or VHK
derived from the anti-progesterone MAb, DB3 (14). West- both in the presence and absence of the secondary anti-
body was analyzed. The results (Table 2) showed thatern blot analyses revealed that the induced cultures con-
tained proteins of approximately 40 kDa that reacted with when mixed with virus alone, VHK was able to only par-
tially neutralize FMDV in a standard plaque reductiongoat anti-mouse IgG (results not shown).
The VHK was purified from the periplasmic extracts by neutralization (PRNT) assay, but in the presence of goat
anti-mouse IgG, the VHK preparations were strongly neu-affinity chromatography on goat anti-mouse IgG coupled
to AffiGel-10 (Bio-Rad). The results (Fig. 2) showed that tralizing.
The VHK 6 product, in the presence of goat anti-mousewhile very little protein could be detected by UV adsorp-
tion in the bound fractions, a strong peak of virus precipi- IgG, was also able to specifically enhance the infection
of FMDV on CHO cells expressing the B2 isoform of thetating activity was evident. The purified VHK was quanti-
tated by running on SDS–PAGE, followed by silver stain- FcR (21; Table 3). Although the levels of infection ob-
served in this experiment were 20- to 50-fold lower thaning, and was compared with known concentrations of
BSA analyzed in the same way. A single band migrating the authentic 2PD11, the VHK-secondary antibody mixture
enhanced infection more than 1000-fold over backgroundat about 40 kDa was observed in the silver-stained gel
(not shown). This analysis revealed that about 400 mg of levels of replication.
Preliminary studies have been done to begin to eluci-material could be recovered from 100 ml of bacterial
culture. A comparison of the ability of the purified VHK date the mechanisms of neutralization by both 2PD11
and the VHK. Both 2PD11 and VHK were incubated withand MAb to immunoprecipitate radiolabeled type A12 re-
vealed that, in the presence of a goat anti-mouse IgG [35S]methionine-labeled virus at different antibody mole-
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FIG. 3. Analysis of the virus-binding activity of purified VHK. Serial
dilutions of MAb 2PD11 (starting concentration 1 mg/ml), or VHK (start-
ing concentration 4 mg/ml) were reacted with 35S-labeled type A12 (17.5
1 103 cpm; specific activity approximately 6 1 1006 cpm/particle) for
1 hr at room temperature. The VHK–virus mixture was incubated for
an additional 30 min with goat anti-mouse IgG (3 mg), prior to the
addition of protein A-expressing Staphylococcus aureus. Bound radio-
activity was eluted in 2% SDS and counted.
FIG. 2. Purification of VHK 6 from a periplasmic extract of E. coli. particle), the gradient was identical to the control (Fig.
Purified goat anti-mouse IgG (Cappel) (10 mg) was coupled to a 2- 5C). An additional 30-min incubation of the virus–VHK
ml Affi-Gel 10 column (Bio-Rad) as described by the manufacturer. complex with goat anti-mouse IgG, at a ratio of 10 anti-
Approximately 100 ml of a periplasmic extract prepared from E. coli
mouse IgG molecules/VHK molecule did not result in anyD29A1 cells transformed with the VHK 6 plasmid (13) was diluted 1:1
aggregation of the virus (Fig. 5D). This ratio of VHK, anti-with column binding buffer (CBB; 100 mM boric acid, 20 mM sodium
borate, 500 mM NaCl, pH 8.2) and passed through the column, at room
temperature, at a rate of 5 ml/hr. The column was extensively washed
with CBB and bound material was eluted with glycine–HCl buffer (0.56
M glycine, 0.2 M NaCl, 0.1 N HCl, pH 3.0) at a rate of 0.5 ml/min.
Fractions (0.5 ml) were collected into 0.2 ml 1 M Tris–HCl, pH 7.5, and
the OD280 was determined. Activity of each fraction was determined by
radioimmunoprecipitation with 35S-labeled type A12 (approx. 6100 cpm)
as described (12) with the added step of incubating the virus–antibody
mixture for an additional 30 min with 3 mg of goat anti-mouse IgG prior
to the addition of protein A-expressing Staphylococcus aureus.
cule/virus particle ratios and the complex was analyzed
by sucrose gradient centrifugation. The results in Fig. 5
show the gradients for the highest antibody/virion ratio
(180 antibody molecules/virus particle). There are 60 epi-
topes per virion, and antibody/virion ratios greater than
10 gave similar results (not shown). Virus incubated with-
out antibody gave a single peak on the gradient with very
few counts in the pellet fraction (Fig. 5A). In contrast, the
virus-2PD11 complex gave a much broader peak, which
seemed to skew toward the bottom of the gradient, and
a much larger number of counts in the pellet (Fig. 5B).
This indicates that while much of the virus remains unag-
gregated, there appear to be large and small virus aggre-
gates formed in the presence of 2PD11. This result is
FIG. 4. Analysis of the specificity of VHK. Purified VHK or MAb 2PD11similar to that seen previously with an unpurified prepa- was used to radioimmunoprecipitate [35S]methionine-labeled types A12 ,
ration of antibody (4). When virus was incubated with the O1 , C3 , A/O, or A/C as described in the legend to Fig. 3. Bound material
was analyzed on a 12.5% polyacrylamide gel.VHK at the same ratio as 2PD11 (180 VHK molecules/virus
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TABLE 2 the RGD sequence on the G–H loop of VP1 (S. Curry,
personal communication), which makes up part of theNeutralization of Type A12 FMDV by VHKa
virus receptor binding site (6, 22). Although this distance
PRN50 (ng/ml)b (27; T. Smith, personal communication) and the reactivity
of the MAb with the antigenic chimeras (25) suggest that
2PD11 VHK the RGD is not part of the 2PD11 contact sites, neutraliza-
tion of virus by the VHK, alone, at high concentrations0 Goat anti-Mo IgG 10 2000
could result from the steric hindrance of this binding site./ Goat anti-Mo IgG NDc 62.5
Addition of the second antibody could augment neutral-
a Virus was diluted in PBS with 1% calf sera to a concentration of 2 ization by either increasing steric hindrance, causing vi-
1 103 PFU/ml, and 100 ml incubated with an equal volume of serial rus aggregation, or cross-linking of capsid structures,
dilutions either 2PD11, at a starting concentration of 1 mg/ml, or VHK preventing viral uncoating. Since it has been shown thatat a starting concentration of about 4 mg/ml, for 1 hr at room tempera-
the conformation of a Fab structure binding to rhinovirusture. The virus–antibody mixtures were then incubated for an additional
30 min with 6 mg of goat anti-mouse IgG prior to inoculating 100 ml of appears to differ from the structure of the native MAb
each mixture (approximately 100 PFU) into BHK-21 cell cultures. After binding (26), it is possible that the VHK might use a differ-
incubation at 377 for 1 hr, the inoculum was removed, the plates were ent mechanism of neutralization than authentic 2PD11.
overlayed with medium containing 0.6% gum tragacanth, and the
The results in this report, however, indicate that bindingplaques were visualized 2 days later as previously described (25).
of VHK either alone or with the second antibody does notb The concentration of antibody which reduced the number of
plaques by 50% of control values. lead to aggregation or inhibition of virus binding to cells
c Not determined. (Fig. 5). In contrast, reaction with VHK results in a dramatic
increase in viral adsorption (Fig. 5E). Since the structure
of the VP1 G–H loop appears to be influenced by the
mouse IgG and virus caused over 90% of the virion VP3 G–H loop structure (11), binding of antibody to the
counts to bind to protein A-containing Staphylococcus VP3 loop may cause the VP1 loop to assume a structure
aureus (not shown), indicating that almost of the virions more favorable for receptor interaction than in native vi-
had bound antibody. These virus–antibody complexes rus. That antibody-complexed virus can infect cells via
were then analyzed in a BHK-21 cell binding assay (Fig. FcR-mediated adsorption (Table 3) indicates that inter-
5E). MAb 2PD11 caused about a 40% reduction in the nalization of the complex does not interfere with viral
level of binding of type A12 , and not all of the binding was eclipse leading to the release of nucleic acid. Therefore,
specific, as evidenced by a lower degree of inhibition by
unlabeled type A12 . Again, this result is similar to that TABLE 3
reported previously using unpurified 2PD11 (4). Surpris-
Enhancement of Infection of FMDV by VHKingly, however, binding of the VHK resulted in a threefold
in Cells Expressing Murine FcRaincrease in virus adsorption which was not significantly
reduced by the addition of anti-mouse IgG. The binding Volume Anti-Mo-IgG Titer
in both cases was specific, since over 90% of the binding Antibody (ml) (mg)b (PFU/ml)c
was inhibited by unlabeled virus (Fig. 5E).
2PD11 (HCF)d 50 0 8.5 1 107A number of neutralizing single-chain antibodies
2PD11 (HCF) 50 3 7.0 1 107against a variety of viruses have been engineered in the
VHK (PPF)e 25 3 1.5 1 106E. coli system (8, 10, 15, 16, 20, 28). However, this is the VHK (PPF) 12.5 3 4.5 1 106
first report of the development of a three-domain VHK VHK (PPF) 25 0.3 1.7 1 103
VHK-DB3 (PPF)f 25 3 1.5 1 103antibody for the picornaviruses. The inclusion of the con-
— — 3 2.0 1 103stant k domain does not hinder VH/VL assembly, while
— — 0.3 2.4 1 103providing a convenient tag for purification and detection
— — — 1.6 1 103
with commercially available anti-mouse k chain antibod-
ies. The original MAb (2PD11) from which our VHK was a Enhancement of infection assays were performed essentially as
described (21). Virus was preincubated with the indicated primary anti-derived reacts with an epitope on the G–H loop of VP3
body and goat anti-mouse IgG mixtures, and used to infect CHO-B2(5) and does not appear to neutralize virus by either
cells. Following an incubation of 1 hr, the inoculum was removed, andaggregation or inhibition of viral binding (4). In the pres-
the monolayers rinsed with MES-buffered saline, pH 6.0, and incubated
ent, more quantitative study, we have found that this in tissue culture media overnight at 377 prior to harvest and plaque
antibody did cause the formation of both small and large assay.
b Goat anti-mouse IgG secondary antibody.aggregates, but left much of the virus unaggregated (Fig.
c Titer of virus recovered, in PFU, measured on BHK cells.5B). This resulted in a lower, but still significant level of
d Hybridoma culture fluid.
specific virus binding to BHK-21 cell receptors (Fig. 5E). e Periplasmic fraction harvested from E. coli expressing the indicated
In the 3-D crystal structure of DTT-treated type O FMD VHK.
f A VHK derived from the anti-progesterone MAb DB3 (14).virions, the 2PD11 epitope lies approximately 30 A˚ from
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FIG. 5. Analysis of virion–antibody complexes by gradient centrifugation and virus adsorption assay. [35S]Methionine-labeled type A12 was
incubated for 1 hr at room temperature alone (A), with purified MAb 2PD11 at a ratio of 180 antibody molecules/virus particle (B), with purified VHK
at a ratio of 180 VHK molecules/virus particle (C), or with purified VHK at the same ratio as in C, but with an additional 30-min incubation with goat
anti-mouse IgG at a ratio of 10 anti-mouse molecules/VHK molecule (D). Samples were either loaded onto 10–50% (w/v) sucrose gradients and
centrifuged at 17,000 rpm for 18 hr in an SW41 rotor at 47, or used to bind to BHK-21 cells at a concentration of 2.5 1 107 cells/ml, which had
previously been incubated for 30 min at room temperature either with (j) or without (h) unlabeled homologous virus at a multiplicity of 1 1 105
particles/cell, for 2 hr at room temperature as previously described (4) (E).
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